- Home
- CUE vs IROQ Comparison
CUE vs IROQ Comparison
Compare CUE & IROQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- IROQ
- Stock Information
- Founded
- CUE 2014
- IROQ 1883
- Country
- CUE United States
- IROQ United States
- Employees
- CUE N/A
- IROQ N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- IROQ Savings Institutions
- Sector
- CUE Health Care
- IROQ Finance
- Exchange
- CUE Nasdaq
- IROQ Nasdaq
- Market Cap
- CUE 77.3M
- IROQ 74.8M
- IPO Year
- CUE 2018
- IROQ 2011
- Fundamental
- Price
- CUE $1.31
- IROQ $24.53
- Analyst Decision
- CUE Strong Buy
- IROQ
- Analyst Count
- CUE 5
- IROQ 0
- Target Price
- CUE $5.00
- IROQ N/A
- AVG Volume (30 Days)
- CUE 406.9K
- IROQ 2.4K
- Earning Date
- CUE 03-10-2025
- IROQ 01-28-2025
- Dividend Yield
- CUE N/A
- IROQ 1.63%
- EPS Growth
- CUE N/A
- IROQ N/A
- EPS
- CUE N/A
- IROQ 0.62
- Revenue
- CUE $9,532,000.00
- IROQ $22,441,000.00
- Revenue This Year
- CUE $73.11
- IROQ N/A
- Revenue Next Year
- CUE $11.02
- IROQ N/A
- P/E Ratio
- CUE N/A
- IROQ $39.32
- Revenue Growth
- CUE 149.53
- IROQ N/A
- 52 Week Low
- CUE $0.45
- IROQ $14.85
- 52 Week High
- CUE $2.93
- IROQ $24.53
- Technical
- Relative Strength Index (RSI)
- CUE 52.47
- IROQ 66.03
- Support Level
- CUE $1.21
- IROQ $22.84
- Resistance Level
- CUE $1.75
- IROQ $24.00
- Average True Range (ATR)
- CUE 0.18
- IROQ 0.27
- MACD
- CUE 0.00
- IROQ 0.08
- Stochastic Oscillator
- CUE 45.00
- IROQ 100.00
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.